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30 
Abstract 31 
Cholesterol is an abundant component of mammalian cell membranes and has been 32 
extensively studied as an artificial membrane stabiliser in a wide range of phospholipid 33 
liposome systems. In this study, the aim was to investigate the role of cholesterol in cationic 34 
liposomal adjuvant system based on dimethyldioctadecylammonium (DDA) and trehalose 35 
6,6’-dibehenate (TDB) which has been shown as a strong adjuvant system for vaccines 36 
against a wide range of diseases. Packaging of cholesterol within DDA:TDB liposomes was 37 
investigated using differential scanning calorimetery and surface pressure-area isotherms of 38 
lipid monolayers; incorporation of cholesterol into liposomal membranes promoted the 39 
formation of a liquid-condensed monolayer and removed the main phase transition 40 
temperature of the system, resulting in an increased bilayer fluidity and reduced antigen 41 
retention in vitro. In vivo biodistribution studies found that this increase in membrane fluidity 42 
did not alter deposition of liposomes and antigen at the site of injection. In terms of immune 43 
responses, early (12 days after immunisation) IgG responses were reduced by inclusion of 44 
cholesterol, thereafter there were no differences in antibody (IgG, IgG1, IgG2b) responses 45 
promoted by DDA:TDB liposomes with and without cholesterol. However, significantly higher 46 
levels of IFN-gamma were induced by DDA:TDB liposomes and liposome-uptake by 47 
macrophages in vitro was also shown to be higher for DDA:TDB liposomes compared to 48 
their cholesterol-containing counterparts, suggesting small changes in bilayer mechanics 49 
can impact both on cellular interactions and immune responses.   50 
 51 
Keywords Vaccine, Adjuvant, Cholesterol, Biodistribution, DDA, bilayer fluidity, liposomes, 52 
subunit antigen. 53 
  54 
 55 
56 
1. Introduction 57 
Liposomes composed of dimethyldioctadecylammonium (DDA) combined with an 58 
immunostimulatory component of the mycobacterial cell wall, trehalose 6,6-dibehenate 59 
(TDB) have been described as having immunostimulatory properties in numerous studies 60 
[e.g. 1-5]. TDB is a synthetic analogue of trehalose 6,6 α-dimycolate (TDM) often referred to 61 
as cord factor. Liposomes made of DDA and TDB, have been subject to stabilising and 62 
sterilisation methods [6] with GMP production already successfully established [7]. An 63 
intrinsic property of the DDA:TDB formulation is its ability to form a strong liposome-antigen 64 
depot at the site of injection after administration via the subcutaneous (s.c.) or intramuscular 65 
(i.m.) route [8], and this has been linked to the formulations ability to induce a powerful Th1 66 
response as well as humoural immune responses [4, 5, 9]. In contrast, injection of antigen 67 
alone, neutral liposomes, or PEGylated cationic liposomes all result in low levels of antigen 68 
and adjuvant retention at the injection site and subsequently induce lower Th1 responses [8, 69 
10, 11]. However, whilst all the formulations that promoted a depot effect were shown to 70 
produce higher immune responses, direct targeting of liposomes to the lymphatics can 71 
stimulate higher immune responses in some instances. One such study [12] investigated the 72 
role of liposome-adjuvant delivery by comparing immune responses of mice immunised via 73 
the intramuscular route and mice immunised via direct injection of the formulation into the 74 
lymph node. Direct injection of DDA or DDA:TDB liposomes intralymphatically made no 75 
notable difference to IgG1 responses in mice compared to those immunised intramuscularly. 76 
However, IgG2a responses in mice were higher after intralymphatical administration of DDA 77 
liposomes, but were not notably different when TDB was incorporated within the formulation 78 
[12]. Similarly, the route of administration was shown to play a critical role in IFN-gamma 79 
responses, with animals immunised with either DDA or DDA:TDB formulations directly into 80 
the lymph node giving significantly higher responses compared to those immunised via the 81 
intramuscular route. Based on these findings, it was important to consider various 82 
formulation strategies that that facilitate the cationic lipid DDA to be used within the adjuvant 83 
formulation, yet which would facilitate enhanced drainage to the lymphatics.  84 
 85 
Cholesterol is an abundant component of mammalian cell membranes and has been 86 
extensively studied in phospholipid liposomal systems as a membrane stabiliser [13 -15]. 87 
The incorporation of cholesterol into liposomal membranes has been shown to lead to 88 
improved lipid packing consequently reducing or even eliminating the main phase transition 89 
temperature [7,16,17]. The resulting lower gel to liquid phase transition temperature leads to 90 
increased bilayer fluidity and liposomes show improved stability both in vitro and in vivo [13]. 91 
Whilst cholesterol is not inherently immunogenic, numerous studies have shown that 92 
incorporation of cholesterol into liposomes leads to more favourable liposome properties 93 
such as increased transfection rates [18] and improved immunogenicity [19].  94 
 95 
Therefore within his present study, we have considered the impact of including cholesterol 96 
within the DDA:TDB liposome adjuvant delivery system, with consideration of its ability to 97 
modulate bilayer fluidity and potentially alter the pharmacokinetic profile of the liposomal-98 
adjuvant system. The packaging of cholesterol within the DDA:TDB bilayer was investigated 99 
using surface pressure-area isotherms and differential scanning calorimetry. In vitro studies 100 
investigating the ability of human macrophage-like cells to interact with liposomes containing 101 
cholesterol at varying molar ratios were compared with in vivo performance, to investigate in 102 
vitro-in vivo correlations. In addition, the ability of liposomes to form an antigen depot at the 103 
site of injection, to present antigen to the immune system, and to generate an immune 104 
response towards the co-administered antigen were investigated.  105 
 106 
2. Materials and Methods 107 
2.1 Materials 108 
Dimethyldioctadecylammonium bromide (DDA) and trehalose 6,6’-dibehenate (TDB) were 109 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Ag85B-ESAT-6 was kindly supplied 110 
by Statens Serum Institute, Denmark. Cholesterol, hydrogen peroxide, Sephadex™ G-75 111 
and bicinchoninic acid protein assay (BCA) components were purchased from Sigma Aldrich 112 
(Dorset, UK). THP-1 cells were obtained from the American Type Culture Collection (via 113 
LGC Standards, Middlesex, UK). Foetal calf serum (FCS) was from Biosera, UK. RPMI was 114 
purchased from PAA (Yeovil, UK). Penicillin-streptomycin-glutamine (100X) was from 115 
Invitrogen, Paisley, UK. For radiolabelling, l-3-phosphatidyl[N-methyl-3H]choline, 1,2-116 
dipalmitoyl (3H-DPPC) was obtained from GE Healthcare (Amersham, UK), Pierce pre-117 
coated iodination tubes from Pierce Biotechnology (Rockford, IL) and 125I (NaI in NaOH 118 
solution), SOLVABLE™ and Ultima Gold™ scintillation fluid were purchased from Perkin 119 
Elmer (Waltham, MA). Methanol and chloroform (both HPLC grade) were purchased from 120 
Fisher Scientific (Leicestershire, UK). Tris-base, obtained from IDN Biomedical, Inc (Aurora, 121 
Ohio) was used to make Tris buffer and adjusted to pH 7.4 using HCl; unless stated 122 
otherwise Tris buffer was used at 10 mM, pH 7.4. 123 
 124 
2.2 Preparation and characterisation of liposomes 125 
Multilamellar vesicles (MLV) were prepared using the previously described lipid-film 126 
hydration method [25]. Briefly, weighed amounts of DDA, TDB and cholesterol were 127 
dissolved in chloroform/methanol (9:1, by volume) and the organic solvent was removed by 128 
rotary evaporation followed by flushing with N2 to form a thin lipid film which was hydrated in 129 
10 mM Tris-buffer at pH 7.4 for 20 minutes at 60 °C, to a final concentration of 1.98 mM 130 
DDA, 0.25 mM TDB and concentrations of cholesterol of 0, 18 or 31 mol% (8:1, 8:2:1 or 131 
8:4:1 DDA:Chol:TDB molar ratio respectively). Ag85B-ESAT-6 antigen was added to 132 
preformed vesicles to a final concentration of 10 µg/mL.  133 
 134 
Physical characterisation of liposomes included vesicle size measurements (using dynamic 135 
light scattering) and zeta potential analysis (using particle electrophoresis); both techniques 136 
used a Brookhaven ZetaPlus (Brookhaven Instruments, Worcs, UK) to which 100 µL of 137 
liposomes were resuspended in 3 ml Tris buffer (1 mM, pH 7.4). 138 
 139 
2.3 Langmuir-Blodgett Isotherms 140 
An automated controlled film balance apparatus (KSV Langmuir Mini-trough, KSV 141 
Instruments Ltd., Helsinki, Finland) equipped with a platinum Wilhemy plate and placed on a 142 
vibration-free table was used to collect the surface pressure-area isotherms as previously 143 
reported [26]. The size of the trough was 24,225.0 mm2 enclosing a total volume of 144 
approximately 220 mL; the subphase was composed of filtered double-distilled water. Lipids 145 
(at a fixed total concentration of 0.5 mg/mL−1) were dissolved in chloroform and 20 µL of 146 
each solution was spread onto the air/water interface with a Hamilton microsyringe, 147 
(precision of ± 0.2 µL). After spreading, the monolayers were left for 10 minutes to allow the 148 
chloroform to evaporate. Thereafter, the molecules underwent constant compression (10 149 
mm/s−1) until the required surface pressure of less than 0.2 mN/m was attained. The spread 150 
monolayer was then compressed or expanded symmetrically with the two barriers until the 151 
desired surface pressure was reached with accuracy within 0.1 mN/m. The experiment was 152 
performed three times using monolayers prepared from different solutions, and with each 153 
monolayer being compressed only once. KSV software (KSV Instruments Ltd) was used for 154 
data analysis. 155 
 156 
2.4 Differential scanning calorimetry 157 
The gel-to-liquid phase transition temperatures were attained for the liposomal dispersions 158 
via DSC and thermograms were acquired using a Pyris Diamond DSC (Perkin Elmer 159 
Instruments LLC, USA). In this study, a scan rate of 10 °C/min was applied, over the range 160 
of 25 °C to 80 °C. All scans were carried out in triplicate. Suspensions were contained in air 161 
tight pans which were sealed immediately upon loading to reduce the effect of evaporation, 162 
with a sample load weight of approximately 10 mg. A reference pan filled with an equal 163 
volume of Tris buffer was used as a reference. This yielded an improved baseline, 164 
achievable through a comparable thermal composition with the sample. Pyris software, 165 
version 5.00.02 (Perkin Elmer Instruments LLC, USA) was used for all data analysis. 166 
 167 
2.5 Quantification of antigen loading and retention 168 
In order to measure antigen loading and to trace its distribution in vivo, Ag85B-ESAT-6 169 
antigen was radio-labelled with 125I using Pierce pre-coated iodination tubes containing 170 
iodination reagent (Pierce Biotechnology, Rockford, IL) and a G-75 Sephadex 171 
chromatography column for separation of 125I-antigen from 125I [8]. Antigen loading to the 172 
various formulations was calculated by measuring radioactivity in supernatant and pellet 173 
fractions after ultracentrifugation. To aid liposome sedimentation during centrifugation, 174 
liposomes were placed in a solution of OVA (1 mg/mL) causing them to form a clear pellet, 175 
and subsequently centrifuged twice (125,000 ×g, 4 °C, 1 hour) to ensure removal of all non-176 
associated antigen as previously reported [8]. Antigen release from liposomes stored in 177 
simulated in vivo conditions was determined using liposomes adsorbing and entrapping 178 
I125-labelled Ag85B-ESAT-6. Aliquots of each formulation were diluted (1:5) using 50 % v/v 179 
FCS in Tris buffer and incubated in a shaking water bath at 37 °C for 96 h. At various time 180 
intervals, samples were centrifuged and Ag85B-ESAT-6 release from liposomes was 181 
calculated by recording the proportion of radioactivity recovered in the supernatant as a 182 
percentage of the total radioactivity added. 183 
 184 
2.6 Immunisation procedures 185 
Five groups of five female C57BL/6 mice (6-10 weeks of age) received doses of liposome 186 
vaccine formulations containing 2 µg of Ag85B-ESAT-6 in a 50 µL volume. One group also 187 
received a non-liposome formulation containing 2 µg of Ag85B-ESAT-6 suspended in 50 µL 188 
PBS. Naïve groups received 50 µL of PBS. Vaccine formulations were administered 189 
intramuscularly, and each mouse received three doses at intervals of two weeks. Serum 190 
samples were taken 12 days after the first injection and at two week intervals thereafter. 191 
 192 
2.6.1 Analysis of Ag85B-ESAT-6 specific antibody isotypes 193 
Serum samples were analysed for the presence of anti-Ag85B-ESAT-6 IgG, IgG1 and IgG2b 194 
antibodies by enzyme-linked immunosorbent assay (ELISA). ELISA plates (flat bottom, high 195 
binding) were coated with 50 µl Ag85B-ESAT-6 per well (3 µg/well) in PBS and incubated at 196 
4 ºC overnight. Plates were washed with phosphate buffered saline/tween buffer (PBST; 40 197 
g NaCI, 1 g KCI, 1 g KH2PO4, 7.2 g Na2HPO4, (2H20) per 5 litres of ddH20, incorporating 198 
~0.4 ml of Tween 20) and blotted firmly onto paper towel. Plates were blocked with 100 µL 199 
per well of 4 % w/v dried semi-skimmed milk powder in PBS. After 1 hour, plates were 200 
washed again and serially-diluted serum samples added. Plates were incubated for 1 hour at 201 
37 ºC, followed by further washing and detection of anti-Ag85B-ESAT-6 antibodies using 202 
horseradish peroxidase conjugated anti-mouse isotype specific immunoglobulins (goat anti-203 
mouse IgG1 and IgG2b), and subsequent addition of substrate solution, 2,2’-azino-bis (3-204 
ethylbenzthiazoline-6-sulfonic acid) (ABTS) in citrate buffer incorporating 5 µL of 30 % 205 
H2O2/50 ml. After 20 minutes, the absorbance was measured at 405 nm using a plate reader 206 
(Bio-Rad, Herts, UK). 207 
 208 
2.6.2 Proliferation of splenocytes ex vivo  209 
To test cells for their ability to respond to antigen in vitro, splenocytes were restimulated with 210 
various concentrations of antigen (0.05, 0.5, 5 µg/mL) and their proliferation, determined by 211 
3H-thymidine uptake, measured. On day 54 mice, (five groups of five mice, i.e. DDA:TDB, 212 
DDA:Chol:TDB 8:2:1 and 8:4:1 molar ratio, antigen and naive) were terminated by cervical 213 
dislocation and their spleens harvested and placed in a 7 mL bijoux containing  5 ml ice cold 214 
PBS. Each spleen was treated individually and kept on ice until processing. Spleens were 215 
gently grinded on a fine wire screen. After allowing the cell suspension to settle for 216 
approximately 5 minutes the liquid was transferred to sterile 20 mL falcon tubes, without 217 
disturbing the cellular debris at the bottom. The cell suspension was centrifuged at 1200 218 
rpm, 15 oC for 10 minutes. After centrifugation the supernatant was removed, the cell 219 
pellet re-suspended in 5 mL RPMI and a cell count performed. The cell number was 220 
adjusted to between 8 x 104 cells/ml. 221 
 222 
For study of antigen specific proliferative responses, serial dilutions of Ag85B-ESAT-6 223 
(0.05, 0.5 and 5 µg/ml) in RPMI were made and 100 µL added per well of a 96-well culture 224 
plate. Wells containing medium only or 3 µg/mL of concanavalin A (ConA) were included in 225 
all experiments as negative and positive controls respectively. Splenocytes (100 µL, 8 x 104 226 
cells/mL) were added to each well making a final well volume of 200 µl. Cultures were 227 
incubated at 37 °C, 5 % CO2, 95 % humidity for 72 h following which 18.5 kBq (0.5 µCi) 3H-228 
thymidine (40 µL in RPMI/well) was added. After a further 24 h incubation under the same 229 
conditions, cells were harvested using a cell harvester (Titertek). For harvesting, media and 230 
cells from each well was aspirated onto a quartz filter mat. Each mat was placed into a 231 
plastic scintillation vial and 5 ml Ultima Gold™ scintillation fluid added/sample. All samples 232 
were counted using a standard 3H scintillation counting protocol. 233 
 234 
2.6.3 Analysis of cytokine production 235 
Splenocytes isolated from mice were plated into 96-well plates (as described previously in 236 
section 2.8.1). Cells were incubated for 40 hours at 37 oC, in a humid 5 % CO2 environment, 237 
after which supernatants were removed and stored at -70 oC for later analysis. Cytokine 238 
levels of IL2, IL-5 and IFN-γ in the cell culture supernatants were quantified using the 239 
DuoSet® capture ELISA kits), purchased from R&D systems, Abingdon, UK) according to the 240 
manufacturer’s instructions. Briefly, ELISA plates were first coated with capture antibody, 241 
followed by washing and blocking. Samples of cell culture supernatants were then added 242 
and cytokines quantified by addition of a biotinylated-detection antibody, detected by an 243 
enzyme marker (Streptavidin-HRP) and substrate solution following repeated incubation and 244 
washing steps. Absorbance was measured at 405 nm (Bio-Rad, Herts, UK). 245 
 246 
2.7 Biodistribution studies 247 
Inbred female BALB/c mice (6-10 weeks of age) were housed in cages within a laminar flow 248 
safety enclosure and provided with irradiated food and filtered drinking water ad libitum. All 249 
experiments adhered to the 1986 Scientific Procedures Act (UK) and were carried out in a 250 
designated establishment. Four to six days prior to injection, two groups of mice were 251 
injected subcutaneously with 200 µL pontamine blue (0.5 % w/v in PBS). Pontamine blue is 252 
an azo dye that has been described as being taken up by macrophages in vivo therefore 253 
allowing for the identification of lymphoid tissue such as lymph nodes. Although pontamine 254 
blue was primarily employed as a lymph node identification marker, it also served as a 255 
marker for identification of infiltrating macrophages to the site of injection.  Liposomes 256 
containing the tracer molecule 3H-DPPC were produced as described previously [8]. To 257 
obtain isotonicity, trehalose was added to the hydrating buffer to a final concentration of 10 258 
% w/v. Mice were injected with Ag85B-ESAT-6 (radiolabelled with125I) adsorbing liposome 259 
(radiolabelled with 3H) formulations (50 µL/dose, i.m injection). At 1, 4 and 14 days post 260 
injection (p.i) mice were terminated by cervical dislocation and tissue from the site of 261 
injection (SOI), local draining lymph node (LN) and spleen removed for analysis of liposome 262 
(3H) and antigen (125I) presence using methods previously described elsewhere [8].  263 
 264 
2.8 Macrophage studies  265 
In vitro studies were performed using the human monocyte cell line THP-1 as previously 266 
described [22, 23]. Briefly, THP-1 cells were resuspended in fresh medium (RPMI 1640 + 10 267 
% v/v FCS) at a density of 5 x 105 cells/mL and stimulated for 48 h with 250 nM 268 
dihydroxyvitamin D3 (Enzo Life Sciences, Exeter UK) to differentiate cells. Prior to use, cells 269 
were resuspended at 2 x 106 cells/mL in fresh RPMI with 10 % v/v FCS. Liposomes (1 270 
mg/mL) were labelled with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine 271 
perchlorate) (DilC) (0.1 mol%) by inclusion of the lipid (dissolved in solvent) in the solvent 272 
evaporation stage of liposome production (as described in section 2.2). To ensure that all 273 
formulations incorporated the DilC fluorophore equally, the fluorescence was measured 274 
using a fluorimeter. Fluorescently labelled liposomes were diluted to a concentration of 10 275 
µg/mL in RPMI, mixed with cells (1:1) in 6 well tissue culture plates and cocultured at 37 °C 276 
in 5 % CO2. At various time-points, 500 µL of co-culture were removed and mixed with ice-277 
cold RPMI prior to immediate analysis. Association of fluorescent liposomes with THP-1 278 
macrophages was analysed using non-fixed cells via flow cytometry using a Beckman-279 
Coulter FC500 cytometer (High Wycombe, UK). For each sample a minimum of 20,000 280 
events were analysed. 281 
  282 
2.9 Statistical analyses 283 
Data was analysed using analysis of variance (ANOVA) followed by the Tukey test to 284 
compare the mean values of different groups. Differences were considered significant when 285 
the p value was less than 0.05.  286 
 287 
3. Results and discussion 288 
3.1 The role of cholesterol in lipid packing. 289 
Cholesterol is a common component in liposomal formulations and its beneficial role as a 290 
stabilising agent in liposomal bilayers is well recognised. Early studies investigating the 291 
effect of liposome composition on drug retention [13] demonstrated that inclusion of 50 mol 292 
% cholesterol within a liposome formulation increased the stability and reduced the 293 
permeability of liposomal bilayers. At molar percentages between 20 - 50 % (depending on 294 
the nature of the phospholipids), cholesterol can dissolve within the lipid bilayer, whereas at 295 
higher concentrations cholesterol can form crystal habits [24].  296 
 297 
To understand the effect of the incorporation of cholesterol on the spatial orientation of the 298 
alkyl chains and the packing ability of DDA:TDB, initially we employed Langmuir studies [17] 299 
and thermal analysis (Figure 1). Figure 1A shows the surface area and pressure isotherm 300 
data of the various lipid combinations. The surface pressure/area isotherm of pure 301 
cholesterol was typical for the structural characteristics of a sterol; up to a mean molecular 302 
area of approximately 38 Å2/molecule, the spread molecules show little interaction. After this 303 
point, the molecules compact to form a condensed monolayer, with the molecules tightly 304 
packed together (Figure 1A). Continued compression of this monolayer results in a collapse 305 
of the monolayer at 45.4 ± 0.4 mN/m and 32.5 ± 1.1 Å2/molecule. In contrast, DDA shows a 306 
surface plot typical of a cationic lipid, where electrostatic repulsion between the head-groups 307 
deters close proximity of the lipids. Hence the plot shows the transition of the monolayer as 308 
compression is applied, initially starting as a gaseous monolayer, where the lipids are large 309 
distance apart, through the expanded monolayer state to a condensed monolayer prior to 310 
collapse (Figure 1A). In line with previous studies [21], the addition of TDB to DDA 311 
liposomes aids packing of the monolayer, by presumably slotting between the cationic DDA 312 
and reducing electrostatic repulsion. Upon addition of increasing amounts of cholesterol to 313 
the DDA:TDB monolayer, the liquid-expanded phase transition seen with DDA:TDB was 314 
removed and there was a direct transition from gaseous to liquid-condensed, with the overall 315 
surface-pressure plot being more akin to the cholesterol plot at high cholesterol 316 
concentrations (DDA:Chol:TDB 8:4:1 molar ratio; Figure 1A). This trend is supported by a 317 
study on cholesterol inclusion within phosphatidylcholine (PC) systems, where Li et al [25] 318 
report that ordered states can be formed faster with fewer packaging defects with 319 
PC/cholesterol mixtures compared to PC alone [25]. Other studies [26] have also found that 320 
cholesterol is able to generate a liquid-ordered phase in PC membranes containing more 321 
than 25 mol % of cholesterol.  322 
Differential scanning calorimetry (DSC) is a widely used method of thermal analysis that has 323 
been applied to investigate and characterise a range of pharmaceutical systems [32]. DDA 324 
lipid bilayers undergo a main phase transition at a characteristic temperature (Tc), with the 325 
lipid chains transferring from a lower temperature gel-phase dominated by ordered alkyl 326 
chain conformations, to a high-temperature fluid-phase characterised by disordered alkyl 327 
chain conformations [28, 29]. From Figure 1B, the phase transition temperature of DDA:TDB 328 
liposome (8:1 molar ratio) was 44.3 ± 0.15°C. Upon addition of cholesterol (at an 8:2:1 molar 329 
ratio; DDA:Chol:TDB molar ratio) there was a reduction in transition temperature to 42.7 ± 330 
0.13°C (Figure 1B). The observation shows that cholesterol not only lowers the melting 331 
temperature, but also the energy required, as the enthalpy required for the transition to occur 332 
for DDA:TDB is 0.10 ± 0.01 J/g compared to the DDA:Chol:TDB (8:2:1 molar ratio) is 0.05 ± 333 
0.01 J/g (Figure 1B). The hydrocarbon chains of lipids within DDA:TDB liposomes crystallise 334 
into the rigid crystalline phase hence producing a Tc at 44.3 ± 0.15°C. However, when 335 
cholesterol is added at DDA:Chol:TDB 8:4:1 molar ratio, there is complete removal of the 336 
transition temperature (Figure 1B) as the cholesterol prevents crystallisation of the 337 
hydrocarbon chains. A similar study [17] has shown that the inclusion of cholesterol at 33 - 338 
50 molar ratio % to liposomes formed of the lipid DSPC also removed the transition [17].  339 
This removal of the gel-liquid crystalline phase transition of liposome vesicles may facilitate 340 
enhanced fluidity of the system. Indeed, this was demonstrated by Coderch et al [30] who 341 
showed that bilayer fluidity (and in their studies, skin penetration) was increased by the 342 
addition of cholesterol to liposomes formulated from lipids with transition temperatures above 343 
the environment they were being used in. Thus, in the case of DDA:TDB, which has a 344 
transition temperature above body temperature, the addition of cholesterol to the liposomes 345 
will increase their fluidity and therefore could impact on the biodistribution of the vesicles 346 
after intramuscular injection. 347 
3.2 The effect of cholesterol on DDA:TDB liposome characteristics.  348 
From Figure 1 it was established that all three formulations tested gave high antigen loading; 349 
due to their cationic nature these systems are able to electrostatically bind the anionic 350 
antigen as previously reported [e.g. 7-11]. Inclusion of cholesterol into liposomes at a molar 351 
ratio of 8:4:1 DDA:Chol:TDB was sufficient to remove the phase transition of the bilayer, 352 
therefore a series of liposome formulations were prepared to consider the impact the 353 
addition of cholesterol had on the liposome phyisco-chemical characteristics. From Table 1, 354 
it can be seen that the incorporation of low levels of cholesterol to DDA:TDB liposomes 355 
(8:2:1 molar ratio) did not make a significant difference to the vesicle size, but did reduce 356 
antigen loading to a small extent (from 97% to 91%; Table 1). However, increasing 357 
cholesterol content to a molar ratio of 8:4:1 DDA:Chol:TDB in the liposome formulation 358 
resulted in a small increase in vesicle size and again a minor reduction in antigen loading 359 
(Table 1). These small changes in size and antigen loading ability are most probably due to 360 
the dilution of the overall cationic content of the liposomes as the cholesterol concentration is 361 
increased. However, given these were only minor changes in the physico-chemical 362 
characteristics, these would not be expected to have a notable impact on vaccine 363 
performance, therefore using these formulations we then evaluated the impact of cholesterol 364 
modified bilayer fluidity on liposomal adjuvant action, both with regards to the biodistribution 365 
and the ability of the liposome to deliver and present antigen successfully.  366 
  367 
3.3 The impact of cholesterol induced fluidity on adjuvant function. 368 
Immunological analyses were undertaken to determine the efficacy of the three liposome 369 
formulations (outlined in Table 1) in terms of antigen delivery and subsequent initiation of 370 
detectable immune responses. Quantification of antigen specific IgG, IgG1, and IgG2b 371 
antibody production, splenocyte proliferation and subsequent cytokine secretion were 372 
analysed. Figure 2 shows the IgG (A), IgG1 and IgG2b (B) responses over time. As 373 
expected, very little antibody production was noted when antigen was administered without 374 
an adjuvant, whereas all liposome formulations were able to induce measurable levels 375 
(Figure 2). When comparing between the formulations, only at day 12 were significant 376 
differences noted with IgG responses from mice immunised with DDA:TDB being 377 
significantly higher (p<0.05) that DDA;Chol:TDB (8:4:1 molar ratio; Figure 2A). At all time-378 
points thereafter, there were no significant differences in antibody responses between the 379 
formulations. 380 
Splenocytes from immunised mice were cultured in the presence of Ag85B-ESAT-6 and their 381 
proliferative abilities and cytokine production (cytokines IFN-γ, IL-2 and IL-5) measured.  382 
Upon restimulation, mice which had been immunised with DDA:TDB liposomes adsorbing 383 
Ag85B-ESAT-6 showed the highest levels of splenocyte proliferation, in line with previous 384 
studies [13]. With increasing cholesterol content there was a trend, although not significant, 385 
of reduced proliferation in response to secondary exposure to antigen (Fig. 3). In correlation 386 
with previous reports [4,5] highlighting the strong Th1 mediating effects of DDA:TDB 387 
liposomes, high levels of IFN-γ were noted when Ag85B-ESAT-6 was co-delivered with 388 
DDA:TDB liposomes (Figure 4A). Whilst no significant differences between DDA:TDB and 389 
DDA:Chol:TDB (8:2:1 molar ratio) liposomes was noted, inclusion of cholesterol at the higher 390 
molar ratio of 8:4:1 resulted in significantly lower levels of IFN-γ and IL-2 (p<0.05) compared 391 
to non-cholesterol containing DDA:TDB liposomes (Fig 4A,B). 392 
IFN-γ is an important correlate of protective immunity and numerous TB vaccine studies 393 
have shown that IFN-γ production is important for TB vaccine efficacy [6, 31, 32]. IL-2 is 394 
another essential signal in directing cell mediated immunity [38], whilst also playing a role in 395 
the humoural response. The production of IL-5 was also investigated as a signal of Th2 396 
polarising abilities; in line with previous studies investing DDA:TDB liposomes, significantly 397 
higher levels of IL-5 were produced compared to delivery of free antigen; however, no 398 
differences were noted between liposomal groups (results not shown). Recent studies [34] 399 
investigating the effect of membrane fluidity compared the immune responses of DDA:TDB 400 
liposomes with liposomes composed of its unsaturated analog dimethyldioleoylammonium 401 
(DODA), the latter of which forms fluid disordered phase liposomes. These studies found 402 
that DDA-based liposomes induced a significantly higher immune response compared to that 403 
obtained with the fluid DODA-based liposomes. This is comparable to the finding in this 404 
study; as the cholesterol content within the liposome formulation is increased, the fluidity of 405 
the bilayer decreases and a reduction in Th1-biased responses are reduced.  406 
 407 
3.4 The impact of cholesterol incorporation within DDA:TDB liposomes on their clearance 408 
from the injection site.   409 
The role of cholesterol in eliciting a liposome or antigen depot-effect at the site of injection, 410 
and the subsequent presence of either component in the local lymph nodes, was 411 
investigated. As cholesterol inclusion at a 8:2:1 molar ratio had no effect in the 412 
aforementioned immunisation studies, only the higher proportion of cholesterol (8:4:1 molar 413 
ratio) was compared against the non-cholesterol containing counterpart. Figure 5 shows the 414 
presence of liposome and Ag85B-ESAT-6 antigen at the SOI after i.m. injection of antigen 415 
adsorbing formulations. DDA:TDB and DDA:Chol:TDB liposomes (Figure 5A) and their 416 
associated antigen (Figure 5B) showed no significant difference in clearance rates from the 417 
injection site, with between 40 - 50 % of the original liposome dose being recovered 2 weeks 418 
p.i. (Figure 5A). With regards to movement of vaccine components to the local draining 419 
lymph node, the data suggests the DDA:TDB liposomes accumulate more rapidly at the 420 
draining lymph nodes over the first 4 days, with accumulation normalising by day 14 421 
between the groups (Figure 5C), yet drainage of the antigen was not influenced by the 422 
presence of cholesterol in the bilayer formulation (Figure 5D). When considering the 423 
movement of infiltrating monocytes to the site of injection [8, 11], there was no notable 424 
difference in the intensity of monocyte recruitment to the injection site when cholesterol was 425 
included into DDA:TDB liposomes (Figure 5E). 426 
 427 
From Figure 5 it can be seen that whilst initially high-levels of both liposomes and antigen 428 
are retained at the site of injection (~80 %; Figure 5 A and B). However by day 4, liposome 429 
levels remain at similar levels, yet antigen levels drop to ~20 % (Figure A and B), suggesting 430 
that the liposomes may not be able to retain high levels of antigen over a longer period. To 431 
consider the ability of these liposome systems to retain antigen, an antigen retention study 432 
was conducted in simulated in vivo conditions (Figure 5F). These results show that whilst the 433 
liposomes +/- cholesterol have similar zeta potential and antigen loading in the suspension 434 
buffer prior to injection; however, when in the presence of other proteins (such as might be 435 
found at the injection site, promoting liposome aggregation depot formation), competition for 436 
electrostatic binding to the cationic liposomes may occur resulting in antigen loss. Further, 437 
the ability of liposomes to retain antigen may also be influenced by cholesterol content 438 
(Figure 5E).   439 
 440 
In a previous study where the movement of vaccine components from the SOI was studied, 441 
more rapid draining of the liposome component was observed when DDA was substituted for 442 
its unsaturated counterpart ‘DODA’ (which results in more fluid liposomes) [34]. However, 443 
whilst here we see that cholesterol inclusion alters the fluidity of DDA:TDB liposomes (when 444 
included at a 8:4:1 molar ratio), this does not translate into altered draining from the injection 445 
site, nor to the draining lymph node after 14 days. However with both formulations, antigen 446 
loss from the depot at the injection site was noted. The reduction in vaccine efficacy seen in 447 
DDA:Chol:TDB (8:4:1 molar ratio) liposomes must therefore be due to a separate factor; 448 
looking at other studies [34, 35] which have analysed the presence of adjuvant and antigen 449 
in APCs, an important correlation between co-localization of both components and 450 
successful responses was seen. Indeed recent studies by Kamath et al. [35] have shown 451 
that synchronisation of dendritic cell activation and antigen exposure is required for the 452 
induction of Th1 responses, but only a small population of DCs require such activation to 453 
promote strong Th1 responses [35]. In these studies the authors demonstrated that mice 454 
immunised with antigen and DDA/TDB liposomes separately but to the same injection site, 455 
induced similar Th2 responses, but weaker Th1 responses than mice immunised with 456 
DDA/TDB with adsorbed antigen  [34]. Similarly in another study [36], antigen administered 457 
alone, one day prior to a standard vaccine was shown to be detrimental for the immune 458 
response, due to the early exposure of APCs to free antigen. Overall, these studies [35, 36] 459 
demonstrate that whilst the depot-effect is important, more important and detrimental to the 460 
ensuing immune response is the pre-exposure of dendritic cells to antigen alone which can 461 
mediate temporary anergy. Therefore inclusion of cholesterol within the formulation may 462 
result in more rapid loss of antigen initially which subsequently normalises between the 463 
formulations, but which could result in increased pre-exposure of DC to antigen alone, 464 
reducing Th1 responses. 465 
 466 
3.5 Interaction of cholesterol containing DDA:TDB liposomes with phagocytes 467 
Given that the difference in bilayer packaging and transition temperature of the DDA:TDB 468 
liposomes formulated with or without cholesterol had no impact on biodistribution but did 469 
impact on Th1 responses, this would suggest that cellular uptake and activation may be 470 
playing a key role in promoting the different immune responses noted. Therefore to quantify 471 
liposome uptake by phagocytes, the human continuous cell line THP-1 was used. 472 
Fluorescence-labelled DDA:TDB and DDA:Chol:TDB (8:2:1 and 8:4:1 molar ratio) liposomes 473 
were co-cultured with THP-1-derived macrophages at a final lipid concentration of 5 µg/mL. 474 
The proportion of macrophages associated with fluorescent liposomes, and the relative 475 
amount of fluorescence associated, was quantified using flow cytometry. Figure 6 shows the 476 
time-dependent uptake of DDA:TDB liposomes (±cholesterol) after application to THP-477 
derived macrophages at 37°C; with increased amounts of cholesterol, each cell associates 478 
with fewer liposomes, as evidenced by less fluorescence (Figure 6B). For DDA:TDB 479 
liposomes, around 75 % of the cells were associated with the liposomes (Figure 6C), which 480 
is in line with previous studies [23]. However, with increasing cholesterol content the 481 
percentage of cells associated with liposomes decreased to ~ 40 % (Figure 6C). Although 482 
the data presented suggests uptake of DDA:TDB liposomes by macrophage in vitro was 483 
higher compared to cholesterol-containing counterparts it is possible that the activity of 484 
DDA:TDB liposomes in the presence/absence of cholesterol may be different in vivo, 485 
particularly given the in vivo biodistribution suggests the liposomes and antigen are present 486 
at the injection site for several days.  487 
From these studies it can be seen that the cholesterol content within the liposomes reduces 488 
liposomal uptake by phagocytes and this may be the contributing factor in the reduced Th1 489 
responses noted in Figure 3 and 4. As found in a number of studies [8, 11], upon injection 490 
with a vaccine antigen, DDA-based liposomes form a vaccine depot at the injection site that 491 
results in a continuous attraction of antigen-presenting cells that engulf a high amount of 492 
adjuvant. These cells are subsequently efficiently activated, as measured by an elevated 493 
expression of the co-stimulatory molecules CD40 and CD86 [34]. Furthermore, a study by 494 
Korsholm et al (2007) [36] proposed that cationic DDA liposomes promote uptake via 495 
endocytosis prior to disruption or fusion with internal cellular membranes, and that the 496 
delivery of associated antigen to cells occurs upon instant contact with the cell surface 497 
through electrostatic interactions prior to active antigen uptake and presentation, which is a 498 
key mechanism behind the adjuvant properties of cationic DDA liposomes. In addition, 499 
inclusion of DSPC into DDA demonstrated that antigen acquisition by APCs was dependent 500 
upon DDA concentration [36]. 501 
 502 
4. Conclusion 503 
In this study, the aim was to investigate the role of cholesterol in the DDA:TDB adjuvant 504 
delivery system. Inclusion of ~30 mol% of cholesterol was able to abolish the transition 505 
temperature of the liposome formulation without notable impact of the vesicle size, zeta 506 
potential and antigen loading. However, whilst inclusion of cholesterol within the DDA:TDB 507 
liposomal adjuvant system could enhance the fluidity of the system, this did not translate to 508 
increased movement to the local lymphatics, nor impact on the recruitment of monocytes to 509 
the injection site, yet it resulted in a reduction in Th1-based immune responses. This would 510 
suggest that the reduction in immune responses is most likely a result of reduced APC 511 
uptake.   512 
 513 
The effect of membrane fluidity has been investigated previously with the use of cationic lipid 514 
DODA exhibiting a low phase transition temperature. In accordance with the results 515 
presented here, these ‘fluid’ liposomes also showed a decreased ability to stimulate 516 
splenocytes to produce the Th1 biased cytokine IFN-γ. It is possible that the increased 517 
liposome rigidity noted with DDA:TDB liposomes, as compared to those including 518 
cholesterol, results in increased exposure of immune cells to the co-presented antigen. 519 
Supporting this theory, the flow cytometry results presented show a clear increase in 520 
liposome uptake of non-cholesterol containing DDA:TDB liposomes.  521 
 522 
The results presented in this study show that a balance between physico-chemical 523 
properties and desired immunological outcome must be considered. Although cholesterol is 524 
widely considered a suitable liposome stabilising compound, we have shown that the strong 525 
Th1 cytokine polarising nature of TDB containing DDA liposomes is forfeited by addition of 526 
cholesterol to levels of ~30 mol% to this liposome formulation.  527 
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Tables and Figures 668 
 669 
Table 1. Characteristics of cationic liposomes.  670 
 671 
Vesicle size, zeta-potential and antigen loading of DDA:TDB formulations with and without 672 
the addition of  cholesterol. Size and zeta-potential were measured in Tris buffer (1 mM) 673 
using a Brookhaven ZetaPlus instrument. Antigen loading was measured using radiolabelled 674 
antigen. Results represent mean ± SD of triplicate experiments. *denotes p<0.01 or greater 675 
in comparison to DDA:TDB. 676 
 677 
Figure 1. The effect of cholesterol on lipid packing. A) Compression isotherm studies of the 678 
pure and mixture of lipid monolayers of DDA, cholesterol, DDA:TDB with the addition of  679 
cholesterol at two different molar ratios 2 and 4 in deionised water at 20 °C. Results are 680 
expressed as the means of three experiments. SD has not been shown for clarity. B) DSC 681 
thermograms of the gel-to-liquid phase transition of DDA:TDB formulations with the addition 682 
of  cholesterol at two different molar ratios 2 and 4. Liposomes were produced via lipid 683 
hydration in 10 mM Tris buffer (pH 7.4). DSC Thermograms were made at 10 °C/minute (600 684 
°C/h) over the tested temperature range of 25-80 °C. One of three thermograms for each 685 
vesicle system is shown with the results representative of three independent experiments. 686 
Figure 2. Ag85B-ESAT-6 specific antibody titres. Groups of five female C57Bl/6, 687 
approximately six weeks old, received doses of liposome formulations containing 2 µg of 688 
Ag85B-ESAT-6 in a 50 µL volume. Vaccine formulations were administered intramuscularly, 689 
and each mouse received three doses at intervals of two weeks. Serum samples were taken 690 
at 12 days after the first administration and at two week intervals thereafter. Anti-Ag85B-691 
ESAT-6 IgG responses (A) the IgG1/IgG2a balance over the period of the study (B) are 692 
shown; anti-Ag85B-ESAT-6 IgG1 and IgG2b were measured by enzyme-linked 693 
immunosorbent assay (ELISA). Results represent mean ± SD reciprocal end point serum 694 
dilution (log10) from five mice. ***Denotes significantly increased antibody titres (p< 0.05) 695 
 696 
Figure 3. Spleen cell proliferation in response to Ag85B-ESAT-6 antigen. Cell proliferation 697 
was measured by incorporation of 3H-thymidine into cultured splenocytes derived from mice 698 
immunised with Ag85B-ESAT-6 antigen containing formulations.  Results represent mean ± 699 
SD of five mice. 700 
 701 
Formulation Molar ratio Size ± SD  
(nm) 
Zeta-potential ± SD 
(mV) 
Antigen loading 
(%) 
DDA:TDB 8:1 586 ± 78 52 ± 5 97 ± 2.1 
DDA:Chol:TDB 
DDA:Chol:TDB 
8:2:1 
8:4:1 
663 ± 66 
737 ± 53* 
47 ± 6 
45 ± 3 
91 ± 1.1* 
87 ± 3.6* 
Figure 4. Ag85B-ESAT-6 specific cytokine production. Cytokines were detected using 702 
DuoSet® capture ELISA kits (mouse IFN-γ (A), IL-2 (B), purchased from R&D systems, 703 
Abingdon, UK) according to the manufacturer’s instructions. Results shown mean+/- SD, 704 
n=5. * denotes significantly increased levels in comparison to naïve controls (n=5, p<0.05).  705 
 706 
Figure 5. Presence of liposome and antigen at the site of injection following intramuscular 707 
injection of Ag85B-ESAT-6 antigen adsorbing to DDA:TDB with and without cholesterol. 708 
Tissue was collected on days 1, 4 and 14 p.i and assayed for the presence of 3H and 125I 709 
relating to  A) liposome and B) antigen at the site of injection, C) liposome and D) antigen at 710 
the popliteal lymph node respectively. Results represent mean ± SD of four mice. E) shows 711 
monocyte infiltration (tracked by pontamine blue) at the SOI (quadriceps) after 14 days 712 
injection (i.m.) of DDA:TDB and DDA:Chol:TDB (8:4:1 molar ratio) liposomes with  adsorbed 713 
Ag85B-ESAT-6 antigen. F) Ag85B-ESAT-6 antigen release profile of DDA:TDB, 8:2:1 and 714 
8:4:1 liposomes using 125I-labelled Ag85B-ESAT-6 when stored under simulated in vivo 715 
conditions (50 % FCS, 37 °C). Results represent mean ± SD of triplicate experiments.  716 
 717 
 Figure 6. The presence of cholesterol in liposomes reduces their interaction with THP-1 718 
cells. THP-1-derived macrophages were co-cultured with dilC-fluorescently labeled 719 
liposomes with the addition of cholesterol at two different molar ratios 2 and 4. At the 720 
indicated timepoints, a sample of cells was removed and immediately analysed using flow 721 
cytometry. Data from a minimum of 20,000 cells are shown: (A) frequency histograms for 722 
fluorescence associated (surface-bound or internalised) with macrophages at the indicated 723 
times, from a representative assay. (B) Mean fluorescence intensity of macrophages 724 
cocultured with the indicated liposomes. (C) Percentage of macrophages positive for 725 
fluorescence. Data shown for parts (B) and (C) are mean ± SEM from three independent 726 
experiments. Statistical analyses used ANOVA with Dunnett’s post test.  *P<0.05 compared 727 
to DDA:TDB (8:1 molar ratio) at each time point. 728 
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